Summary
2′-Deoxy-5-azacytidine (5-aza-CdR) and cisplatin interact to produce synergistic cytotoxicity against many human tumor cell lines. Preliminary experiments designed to explore the mechanism of this synergy suggested a poor correlation between synergy and the degree of genomic hypomethylation measured following exposure to 5-aza-CdR. Subsequent studies using plasmid DNA suggested that rather than DNA hypomethylation, incorporation of 5-aza-CdR into DNA mediated increased cisplatin binding to DNA and could therefore be essential to the synergistic interaction between these two agents. In this series of experiments, we evaluated the degree of synergy with cisplatin produced against two human melanoma cell lines by two additional antimetabolites that were chosen on the basis of their biochemical properties. In addition, we investigated the synergy between 5-aza-CdR and cisplatin in parental and 5-aza-CdR-resistant murine cell lines, which differed in their sensitivity to 5-aza-CdR and DNA methylation status but incorporated similar amounts of 5-aza-CdR into DNA when exposed to this antimetabolite. In the studies testing additional antimetabolites, cytosine arabinoside, which is incorporated into DNA but does not hypomethylate it, produced synergy with cisplatin that was similar or superior to that obtained using 5-aza-CdR. With 3-deaza-adenosine, which is not incorporated into DNA but produces DNA hypomethylation through inhibition of S-adenosylhomocysteine hydrolase, a primarily antagonistic interaction was observed in the two cell lines studied. In the 5-aza-CdR-sensitive and-resistant cell lines, a very similar synergistic interaction was documented for 5-aza-CdR and cisplatin despite the significant difference observed in DNA methylation levels. Taken as a whole, these data suggest that DNA hypomethylation was not critical to the synergistic cytotoxicity produced by 5-aza-CdR and cisplatin. This finding suggests additional strategies that could further modulate this interaction.
Similar content being viewed by others
References
Aggarwal BB, Eessalu TE, Hass PE (1985) Characterization of receptors for human tumor necrosis factor and their regulation by interferon. Nature 318: 665
Albino AP, Lloyd KO, Houghton AN, Oettgen HF, Old FJ (1981) Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. J Exp Med 154: 1764
Benz C, DeGregorio M, Saks S, Sambol N, Holleran W, Ignoffo R, Lewis B, Cadman E (1985) Sequential infusions of methotrexate and 5-fluorouracil in advanced cancer: pharmacology, toxicity, and response. Cancer Res 45: 3354
Bergerat JP, Drewinko B, Corry P, Barlogie B, Ho DH (1981) Synergistic lethal effect ofcis-dichlorodiammineplatinum and 1-β-d-arabinofuranosylcytosine. Cancer Res 41: 25
Chou J, Chou T-C (1987) Dose effect analysis with microcomputers. Elsevier-Biosoft, Cambridge, United Kingdom
Chou T-C (1977) On the determination of availability of ligand binding sites in steady state systems. J Theor Biol 65: 345
Chou T-C, Talalay P (1983) Analyses of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 4: 450
Chou T-C, Talalay P (1984) Quantitative analysis of dose effect relationships: the combined effects of multiple drugs on enzyme inhibitors. Adv Enzyme Regul 22: 27
Cory JG (1988) Ribonucleotide reductase as a chemotherapeutic target. Adv Enzyme Regul 27: 437
Creusot F, Acs G, Christman JK (1982) Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J Biol Chem 257: 2041
Djurhuus R, Svardal AM, Veland PM (1989) Differential effects on growth, homocysteine, and related compounds of two inhibitors of S-adenosylhomocysteine catabolism, 3-deazaadenosine, and 3-deazaaristeromycin in C3H/10T1/2 cells. Cancer Res 49: 324
Flatau E, Bogenmann E, Jones PA (1983) Variable 5-methylcytosine levels in human tumor cell lines and fresh pediatric tumor explants. Cancer Res 43: 4901
Flatau E, Gonzales FA, Michalowsky LA, Jones PA (1984) DNA methylation in 5-aza-2′-deoxycytidine-resistant variants of C3H 10T1/2 C18 cells. Mol Cell Biol 4: 2098
Fram RJ, Robichaud N, Bishov SD, Wilson JM (1987) Interactions ofcis-diamminedichloroplatinum (II) with 1-β-d-arabinofuranosylcytosine in LoVo colon carcinoma cells. Cancer Res 47: 3360
Frost P, Abbruzzese JL, Hunt B, Lee D, Ellis M (1990) Synergistic cytotoxicity usign 2′-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells. Cancer Res 50: 4572
Grem JL, Allegra CJ (1990) Enhancement of the toxicity and DNA incorporation of arabinosyl-5-azacytosine and 1-β-d-arabinofuranosylcytosine by cyclopentenyl cytosine. Cancer Res 50: 7279
Jones PA, Taylor SM (1980) Cellular differentiation, cytidine analogs, and DNA methylation. Cell 20: 85
Kozolowski JM, Hart IR, Fidler IJ, Hanna N (1984) A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice. J Natl Cancer Inst 72: 913
Liteplo RG (1988) DNA (cytosine) methylation in murine and human tumor cell lines treated with S-adenosylhomocysteine hydrolase inhibitors. Cancer Lett 39: 319
McGhee JD, Ginder GD (1979) Specific methylation sites in the vicinity of the chicken B-globin genes. Nature 280: 419
Michalowsky LA, Jones PA (1987) Differential nuclear protein binding to 5-azacytosine-containing DNA as a potential mechanism for 5-aza-2′-deoxycytidine resistance. Mol Cell Biol 7: 3076
Momparler RL, Derse D (1979) Kinetics of phosphorylation of 5-aza-2′-deoxycytidine by deoxycytidine kinase. Biochem Pharmacol 28: 1443
Nyce J (1989) Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res 49: 5829
Razin A, Riggs AD (1980) DNA methylation and gene function. Science 210: 604
Schiller JH, Bittner G, Storer B, Willson JKV (1987) Synergistic antitumor effects of tumor neerosis factor and γ-interferon on human colon carcinoma cell lines. Cancer Res 47: 2809
Vadi H, Drewinko B (1986) Kinetics and mechanism of the 1-β-d-arabinofuranosylcytosine-induced potentiation ofcis-diamminedichloroplatinum(II) cytotoxicity. Cancer Res 46: 1105
Veselý J, Čihák A (1977) Incorporation of a potent antileukemic agent 5-aza-2′-deoxycytidine into DNA of cells from leukemic mice. Cancer Res 37: 3684
Wadler SW, Schwartz EL, Goldman M, Lyver A, Rader M, Zimmerman M, Itri L, Weinberg V, Wiernik PH (1989) Fluorouracil and recombinant alpha-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 7: 1769
Wilson VL, Jones PA, Momparler RL (1983) Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2′-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res 43: 3493
Author information
Authors and Affiliations
Additional information
Supported in part by grants CA39853 and CA41524 from the United States Public Health Service
Rights and permissions
About this article
Cite this article
Abbruzzese, J.L., Frost, P. Studies on the mechanism of the synergistic interaction between 2′-deoxy-5-azacytidine and cisplatin. Cancer Chemother. Pharmacol. 30, 31–36 (1992). https://doi.org/10.1007/BF00686482
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686482